Advantages of replacing the total PSA assay with the assay for PSA-α1-antichymotrypsin complex for the screening and management of prostate cancer

被引:0
|
作者
Wu, JT
Liu, GH
机构
[1] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Associated Reg Univ Pathologists, ARUP, Salt Lake City, UT USA
关键词
benign prostate hyperplasia; free PSA; percent-free PSA;
D O I
10.1002/(SICI)1098-2825(1998)12:1<32::AID-JCLA6>3.0.CO;2-L
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Several advantages become immediately apparent when the prostate specific antigen (PSA, or tPSA) assay is replaced by the assay specific for the serum PSA-alpha 1-antichymotrypsin (PSA-ACT) complex. For instance, random contributions to the tPSA value by various serum minor PSA isoforms can be avoided, making possible the determination of a more accurate relation of the PSA-ACT concentration to the tumor activity. Discrepancies in percent free PSA (% fPSA) values from the same specimens due to the use of different commercial kits also can be eliminated, mainly because the PSA-ACT assay does not have the problems in antibody selection and calibrator preparation usually associated with the tPSA assay. We found that at the present time different cutoffs of % fPSA for the differentiation of BPH from prostate cancer must be established for each individual tPSA assay. Cutoffs established using values from one tPSA assay should not be used for making clinical decisions when their tPSA values are determined by a different kit. Moreover, when we monitored the patients during treatment with serum tPSA, specific fPSA, and specific PSA-ACT complex assays simultaneously, it was clear that any interpretation of the patient's clinical status based on tPSA values alone could be misleading. Because there is less PSA-ACT complex in BPH specimens relative to that found in cancer serum samples, expressing fPSA as "fPSA/ PSA-ACT x 100" and measuring PSA-ACT complex concentrations instead of tPSA during screening improve the measurable contrast between BPH and prostate cancer. Although individually modest, collectively these advantages can add up to considerable improvements. (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:32 / 40
页数:9
相关论文
共 50 条
  • [21] Correlation between the Complex PSA/total PSA Ratio and the Free PSA/total PSA Ratio, Sensitivity and Specificity of Both Markers for the Diagnosis of Prostate Cancer
    Perez-Lanzac-Lorca, A.
    Barco-Sanchez, A.
    Romero, E.
    Martinez-Peinado, A.
    Lopez-Elorza, F.
    Sanchez-Sanchez, E.
    Alvarez-Ossorio-Fernandez, J. L.
    Castineiras-Fernandez, J.
    ACTAS UROLOGICAS ESPANOLAS, 2013, 37 (08): : 498 - 503
  • [22] Diagnostic Performance of the Atellica IM Free PSA Assay in Men Undergoing Prostate Cancer Screening
    Nissen, K. Olson
    Snyder, J.
    Pagano, M.
    Owusu, A.
    Grosett, M.
    Birmingham, N.
    Christenson, R.
    Defilippi, C.
    CLINICAL CHEMISTRY, 2024, 70 : I266 - I266
  • [23] Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels
    Reissigl, A
    Klocker, H
    Pointner, J
    Ennemoser, O
    Falk, M
    Bartsch, G
    PROSTATE, 1997, 30 (04): : 243 - 247
  • [24] Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer
    Murthy, Vedang
    Rishi, Anupam
    Gupta, Sanjeev
    Kannan, Sadhana
    Mahantshetty, Umesh
    Tongaonkar, Hemant
    Bakshi, Ganesh
    Prabhash, Kumar
    Bhanushali, Paresh
    Shinde, Bhoopal
    Inamdar, Nitin
    Shrivastava, Shyamkishore
    CLINICAL BIOCHEMISTRY, 2016, 49 (1-2) : 79 - 84
  • [25] Analytical evaluation of the new Prostatus(TM) PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer
    Blijenberg, BG
    Bangma, CH
    Kranse, R
    Eman, I
    Schroder, FH
    EUROPEAN JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1997, 35 (02): : 111 - 114
  • [26] Inhibition of prostate-specific antigen (PSA) by α1-antichymotrypsin:: Salt-dependent activation mediated by a conformational change
    Hsieh, MC
    Cooperman, BS
    BIOCHEMISTRY, 2002, 41 (09) : 2990 - 2997
  • [27] Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers
    Todd Morgan
    Ganesh Palapattu
    John Wei
    Current Urology Reports, 2015, 16
  • [28] Alpha1-antichymotrypsin-PSA (ACT-PSA):: A useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter, W
    Stieber, P
    Schmeller, N
    Nagel, D
    Fateh-Moghadam, A
    ANTICANCER RESEARCH, 1997, 17 (6D) : 4767 - 4770
  • [29] Diagnostic Performance of the Atellica IM High-Sensitivity PSA Assay in Men Undergoing Prostate Cancer Screening
    Nissen, K. Olson
    Snyder, J.
    Pagano, M.
    Owusu, A.
    Grosett, M.
    Birmingham, N.
    Christenson, R.
    Defilippi, C.
    CLINICAL CHEMISTRY, 2024, 70 : I267 - I267
  • [30] The clinical impact of the PSA assay who calibration on prostate biopsy rates and prostate cancer detection
    Jansen, Flip H.
    Roobol, Monique J.
    Bangma, Chris H.
    van Schaik, Ron H. N.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 602 - 603